HIV Accessory Genes Vif and Vpu

Advances in Pharmacology

Volumn 55, Issue , 2007, Pages 199-232

  Strebel, Klaus ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIF PROTEIN; VPU PROTEIN;

AMINO ACID SEQUENCE; ANIMAL; CHEMISTRY; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLISM; MOLECULAR GENETICS; PATHOGENICITY; PHYSIOLOGY; REVIEW; SPECIES DIFFERENCE; VIROLOGY;

AMINO ACID SEQUENCE; ANIMALS; GENE PRODUCTS, VIF; GENE PRODUCTS, VPU; HIV; HIV INFECTIONS; HUMANS; MOLECULAR SEQUENCE DATA; SPECIES SPECIFICITY;

EID: 34250653701     PISSN: 10543589     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1054-3589(07)55006-4     Document Type: Review

References (193)

1. Abada P., Noble B., and Cannon P.M. Functional domains within the human immunodeficiency virus type 2 envelope protein required to enhance virus production. J. Virol. 79 (2005) 3627-3638
2. Addo M.M., Altfeld M., Rathod A., Yu M., Yu X.G., Goulder P.J., Rosenberg E.S., and Walker B.D. HIV-1 Vpu represents a minor target for cytotoxic T lymphocytes in HIV-1-infection. AIDS 16 (2002) 1071-1073
3. Akari H., Bour S., Kao S., Adachi A., and Strebel K. The human immunodeficiency virus type 1 accessory protein Vpu induces apoptosis by suppressing the nuclear factor kappaB-dependent expression of antiapoptotic factors. J. Exp. Med. 194 (2001) 1299-1311
4. Badley A.D., Pilon A.A., Landay A., and Lynch D.H. Mechanisms of HIV-associated lymphocyte apoptosis. Blood 96 (2000) 2951-2964
5. Bai C., Sen P., Hofmann K., Ma L., Goebl M., Harper J.W., and Elledge S.J. SKP1 connects cell cycle regulators to the ubiquitin proteolysis machinery through a novel motif, the F-box. Cell 86 (1996) 263-274
6. Baraz L., Friedler A., Blumenzweig I., Nussinuv O., Chen N., Steinitz M., Gilon C., and Kotler M. Human immunodeficiency virus type 1 Vif-derived peptides inhibit the viral protease and arrest virus production. FEBS Lett. 441 (1998) 419-426
7. Barkett M., and Gilmore T.D. Control of apoptosis by Rel/NF-kappaB transcription factors. Oncogene 18 (1999) 6910-6924
8. Besnard-Guerin C., Belaidouni N., Lassot I., Segeral E., Jobart A., Marchal C., and Benarous R. HIV-1 Vpu sequesters {beta}-transducin repeat-containing protein ({beta}TrCP) in the cytoplasm and provokes the accumulation of {beta}-catenin and other SCF{beta}TrCP substrates. J. Biol. Chem. 279 (2004) 788-795
9. Blanc D., Patience C., Schulz T.F., Weiss R., and Spire B. Transcomplementation of VIF- HIV-1 mutants in CEM cells suggests that VIF affects late steps of the viral life cycle. Virology 193 (1993) 186-192
10. Boge M., Wyss S., Bonifacino J.S., and Thali M. A membrane-proximal tyrosine-based signal mediates internalization of the HIV-1 envelope glycoprotein via interaction with the AP-2 clathrin adaptor. J. Biol. Chem. 273 (1998) 15773-15778
11. Bogerd H.P., Doehle B.P., Wiegand H.L., and Cullen B.R. A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor. Proc. Natl. Acad. Sci. USA 101 (2004) 3770-3774
12. Borman A.M., Quillent C., Charneau P., Dauguet C., and Clavel F. Human immunodeficiency virus type 1 Vif-mutant particles from restrictive cells: Role of Vif in correct particle assembly and infectivity. J. Virol. 69 (1995) 2058-2067
13. Bour S., and Strebel K. The human immunodeficiency virus (HIV) type 2 envelope protein is a functional complement to HIV type 1 Vpu that enhances particle release of heterologous retroviruses. J. Virol. 70 (1996) 8285-8300
14. Bour S., Boulerice F., and Wainberg M.A. Inhibition of gp160 and CD4 maturation in U937 cells after both defective and productive infections by human immunodeficiency virus type 1. J. Virol. 65 (1991) 6387-6396
15. Bour S., Schubert U., and Strebel K. The human immunodeficiency virus type 1 Vpu protein specifically binds to the cytoplasmic domain of CD4: Implications for the mechanism of degradation. J. Virol. 69 (1995) 1510-1520
16. Bour S., Schubert U., Peden K., and Strebel K. The envelope glycoprotein of human immunodeficiency virus type 2 enhances viral particle release: A Vpu-like factor?. J. Virol. 70 (1996) 820-829
17. Bour S., Perrin C., Akari H., and Strebel K. The Human immunodeficiency virus type 1 Vpu protein inhibits NF-kappa B activation by interfering with beta TrCP-mediated degradation of Ikappa B. J. Biol. Chem. 276 (2001) 15920-15928
18. Bour S., Akari H., Miyagi E., and Strebel K. Naturally occurring amino acid substitutions in the HIV-2 ROD envelope glycoprotein regulate its ability to augment viral particle release. Virology 309 (2003) 85-98
19. Bour S.P., Aberham C., Perrin C., and Strebel K. Lack of effect of cytoplasmic tail truncations on human immunodeficiency virus type 2 ROD env particle release activity. J. Virol. 73 (1999) 778-782
20. Bouyac M., Courcoul M., Bertoia G., Baudat Y., Gabuzda D., Blanc D., Chazal N., Boulanger P., Sire J., Vigne R., and Spire B. Human immunodeficiency virus type 1 Vif protein binds to the Pr55Gag precursor. J. Virol. 71 (1997) 9358-9365
21. Buonocore L., and Rose J.K. Prevention of HIV-1 glycoprotein transport by soluble CD4 retained in the endoplasmic reticulum. Nature 345 (1990) 625-628
22. Buonocore L., and Rose J.K. Blockade of human immunodeficiency virus type 1 production in CD4+ T cells by an intracellular CD4 expressed under control of the viral long terminal repeat. Proc. Natl. Acad. Sci. USA 90 (1993) 2695-2699
23. Callahan M.A., Handley M.A., Lee Y.H., Talbot K.J., Harper J.W., and Panganiban A.T. Functional interaction of human immunodeficiency virus type 1 Vpu and Gag with a novel member of the tetratricopeptide repeat protein family. J. Virol. 72 (1998) 5189-5197
24. Camaur D., and Trono D. Characterization of human immunodeficiency virus type 1 Vif particle incorporation. J. Virol. 70 (1996) 6106-6111
25. Carr J.M., Davis A.J., Coolen C., Cheney K., Burrell C.J., and Li P. Vif-deficient HIV reverse transcription complexes (RTCs) are subject to structural changes and mutation of RTC-associated reverse transcription products. Virology 351 (2006) 80-91
26. Casella C.R., Rapaport E.L., and Finkel T.H. Vpu increases susceptibility of human immunodeficiency virus type 1-infected cells to fas killing. J. Virol. 73 (1999) 92-100
27. Chen M.Y., Maldarelli F., Karczewski M.K., Willey R.L., and Strebel K. Human immunodeficiency virus type 1 Vpu protein induces degradation of CD4 in vitro: The cytoplasmic domain of CD4 contributes to Vpu sensitivity. J. Virol. 67 (1993) 3877-3884
28. Chen Y.M., Rey W.Y., Lan Y.C., Lai S.F., Huang Y.C., Wu S.I., Liu T.T., and Hsiao K.J. Antibody reactivity to HIV-1 Vpu in HIV-1/AIDS patients on highly active antiretroviral therapy. J. Biomed. Sci. 10 (2003) 266-275
29. Chiu Y.L., Soros V.B., Kreisberg J.F., Stopak K., Yonemoto W., and Greene W.C. Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells. Nature 435 (2005) 108-114
30. Chiu Y.L., Witkowska H.E., Hall S.C., Santiago M., Soros V.B., Esnault C., Heidmann T., and Greene W.C. High-molecular-mass APOBEC3G complexes restrict alu retrotransposition. Proc. Natl. Acad. Sci. USA 103 42 (2006) 15588-15593
31. Clavel F., Guyader M., Guetard D., Salle M., Montagnier L., and Alizon M. Molecular cloning and polymorphism of the human immunodeficiency virus type 2. Nature 324 (1986) 691-695
32. Coadou G., Evrard-Todeschi N., Gharbi-Benarous J., Benarous R., and Girault J.P. HIV-1 encoded virus protein U (Vpu) solution structure of the 41-62 hydrophilic region containing the phosphorylated sites Ser52 and Ser56. Int. J. Biol. Macromol. 30 (2002) 23-40
33. Coady M.J., Daniel N.G., Tiganos E., Allain B., Friborg J., Lapointe J.Y., and Cohen E.A. Effects of Vpu expression on Xenopus oocyte membrane conductance. Virology 244 (1998) 39-49
34. Cohen E.A., Terwilliger E.F., Sodroski J.G., and Haseltine W.A. Identification of a protein encoded by the vpu gene of HIV-1. Nature 334 (1988) 532-534
35. Conticello S.G., Harris R.S., and Neuberger M.S. The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Curr. Biol. 13 (2003) 2009-2013
36. Courcoul M., Patience C., Rey F., Blanc D., Harmache A., Sire J., Vigne R., and Spire B. Peripheral blood mononuclear cells produce normal amounts of defective Vif- human immunodeficiency virus type 1 particles which are restricted for the preretrotranscription steps. J. Virol. 69 (1995) 2068-2074
37. Crise B., Buonocore L., and Rose J.K. CD4 is retained in the endoplasmic reticulum by the human immunodeficiency virus type 1 glycoprotein precursor. J. Virol. 64 (1990) 5585-5593
38. Deora A., and Ratner L. Viral protein U (Vpu)-mediated enhancement of human immunodeficiency virus type 1 particle release depends on the rate of cellular proliferation. J. Virol. 75 (2001) 6714-6718
39. Dettenhofer M., and Yu X.F. Highly purified human immunodeficiency virus type 1 reveals a virtual absence of Vif in virions. J. Virol. 73 (1999) 1460-1467
40. Dettenhofer M., Cen S., Carlson B.A., Kleiman L., and Yu X.F. Association of human immunodeficiency virus type 1 Vif with RNA and its role in reverse transcription. J. Virol. 74 (2000) 8938-8945
41. Ewart G.D., Sutherland T., Gage P.W., and Cox G.B. The Vpu protein of human immunodeficiency virus type 1 forms cation-selective ion channels. J. Virol. 70 (1996) 7108-7115
42. Fan L., and Peden K. Cell-free transmission of Vif mutants of HIV-1. Virology 190 (1992) 19-29
43. Federau T., Schubert U., Flossdorf J., Henklein P., Schomburg D., and Wray V. Solution structure of the cytoplasmic domain of the human immunoodeficiency virus type 1 encoded virus protein U (Vpu). Int. J. Peptide Res. 47 (1996) 297-310
44. Fisher A.G., Ensoli B., Ivanoff L., Chamberlain M., Petteway S., Ratner L., Gallo R.C., and Wong-Staal F. The sor gene of HIV-1 is required for efficient virus transmission in vitro. Science 237 (1987) 888-893
45. Fouchier R.A., Simon J.H., Jaffe A.B., and Malim M.H. Human immunodeficiency virus type 1 Vif does not influence expression or virion incorporation of gag-, pol-, and env-encoded proteins. J. Virol. 70 (1996) 8263-8269
46. Friborg J., Ladha A., Goettlinger H., Haseltine W.A., and Cohen E.A. Functional analysis of the phosphorylation sites on the human immunodeficiency virus type 1 Vpu protein. J. Acquired Immune Def. Syndr. Hum Retrovir. 8 (1995) 10-22
47. Friedler A., Blumenzweig I., Baraz L., Steinitz M., Kotler M., and Gilon C. Peptides derived from HIV-1 Vif: A non-substrate based novel type of HIV-1 protease inhibitors. J. Mol. Biol. 287 (1999) 93-101
48. Friedler A., Zakai N., Karni O., Friedler D., Gilon C., and Loyter A. Identification of a nuclear transport inhibitory signal (NTIS) in the basic domain of HIV-1 Vif protein. J. Mol. Biol. 289 (1999) 431-437
49. Fujita K., Omura S., and Silver J. Rapid degradation of CD4 in cells expressing HIV-1 Env and Vpu is blocked by proteasome inhibitors. J. Gen. Virol. 78 (1997) 619-625
50. Fujita M., Matsumoto S., Sakurai A., Doi N., Miyaura M., Yoshida A., and Adachi A. Apparent lack of trans-dominant negative effects of various vif mutants on the replication of HIV-1. Microbes Infect. 4 (2002) 1203-1207
51. Fujita M., Akari H., Sakurai A., Yoshida A., Chiba T., Tanaka K., Strebel K., and Adachi A. Expression of HIV-1 accessory protein Vif is controlled uniquely to be low and optimal by proteasome degradation. Microbes Infect. 6 (2004) 791-798
52. Gabuzda D.H., Lawrence K., Langhoff E., Terwilliger E., Dorfman T., Haseltine W.A., and Sodroski J. Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes. J. Virol. 66 (1992) 6489-6495
53. Gabuzda D.H., Li H., Lawrence K., Vasir B.S., Crawford K., and Langhoff E. Essential role of vif in establishing productive HIV-1 infection in peripheral blood T lymphocytes and monocyte/macrophages. J. Acq. Immune Def. Syndr. 7 (1994) 908-915
54. Gallo R., Wong-Staal F., Montagnier L., Haseltine W.A., and Yoshida M. HIV/HTLV gene nomenclature. Nature 333 (1988) 514
55. Gallois-Montbrun S., Kramer B., Swanson C.M., Byers H., Lynham S., Ward M., and Malim M.H. Antiviral protein APOBEC3G localizes to ribonucleoprotein complexes found in P bodies and stress granules. J. Virol. 81 (2007) 2165-2178
56. Garrett E.D., Tiley L.S., and Cullen B.R. Rev activates expression of the human immunodeficiency virus type 1 vif and vpr gene products. J. Virol. 65 (1991) 1653-1657
57. Geraghty R.J., and Panganiban A.T. Human immunodeficiency virus type 1 Vpu has a CD4- and an envelope glycoprotein-independent function. J. Virol. 67 (1993) 4190-4194
58. Gomez L.M., Pacyniak E., Flick M., Hout D.R., Gomez M.L., Nerrienet E., Ayouba A., Santiago M.L., Hahn B.H., and Stephens E.B. Vpu-mediated CD4 down-regulation and degradation is conserved among highly divergent SIV(cpz) strains. Virology 335 (2005) 46-60
59. Goncalves J., Jallepalli P., and Gabuzda D.H. Subcellular localization of the Vif protein of human immunodeficiency virus type 1. J. Virol. 68 (1994) 704-712
60. Goncalves J., Shi B., Yang X., and Gabuzda D. Biological activity of human immunodeficiency virus type 1 Vif requires membrane targeting by C-terminal basic domains. J. Virol. 69 (1995) 7196-7204
61. Gottlinger H.G., Dorfman T., Cohen E.A., and Haseltine W.A. Vpu protein of human immunodeficiency virus type 1 enhances the release of capsids produced by gag gene constructs of widely divergent retroviruses. Proc. Natl. Acad. Sci. USA 90 (1993) 7381-7385
62. Gurland G., and Gundersen G.G. Stable, detyrosinated microtubules function to localize vimentin intermediate filaments in fibroblasts. J. Cell Biol. 131 (1995) 1275-1290
63. Guy B., Geist M., Dott K., Spehner D., Kieny M.P., and Lecocq J.P. A specific inhibitor of cysteine proteases impairs a vif-dependent modification of human immunodeficiency virus type 1 env protein. J. Virol. 65 (1991) 1325-1331
64. Handley M.A., Paddock S., Dall A., and Panganiban A.T. Association of Vpu-binding protein with microtubules and Vpu-dependent redistribution of HIV-1 Gag protein. Virology 291 (2001) 198-207
65. Harila K., Prior I., Sjoberg M., Salminen A., Hinkula J., and Suomalainen M. Vpu and Tsg101 regulate intracellular targeting of the human immunodeficiency virus type 1 core protein precursor Pr55gag. J. Virol. 80 (2006) 3765-3772
66. Hatakeyama S., Kitagawa M., Nakayama K., Shirane M., Matsumoto M., Hattori K., Higashi H., Nakano H., Okumura K., Onoe K., Good R.A., and Nakayama K.I. Ubiquitin-dependent degradation of IkappaBalpha is mediated by aubiquitin ligase Skp1/Cul 1/F-box protein FWD1. Proc. Natl. Acad. Sci. USA 96 (1999) 3859-3863
67. Henklein P., Schubert U., Kunert O., Klabunde S., Wray V., Kloeppel K.D., Kiess M., Porstmann T., and Schomburg D. Synthesis and characterization of the hydrophilic C-terminal domain of the human immunodeficiency virus type 1-encoded virus protein U (Vpu). Pept. Res. 6 (1993) 79-87
68. Henklein P., Kinder R., Schubert U., and Bechinger B. Membrane interactions and alignment of structures within the HIV-1 Vpu cytoplasmic domain: Effect of phosphorylation of serines 52 and 56. FEBS Lett. 482 (2000) 220-224
69. Henriet S., Richer D., Bernacchi S., Decroly E., Vigne R., Ehresmann B., Ehresmann C., Paillart J.C., and Marquet R. Cooperative and specific binding of Vif to the 5′ region of HIV-1 genomic RNA. J. Mol. Biol. 354 (2005) 55-72
70. Hochstrasser M. Protein degradation or regulation: Ub the judge. Cell 84 (1996) 813-815
71. Hoglund S., Ohagen A., Lawrence K., and Gabuzda D. Role of vif during packing of the core of HIV-1. Virology 201 (1994) 349-355
72. Hout D.R., Gomez M.L., Pacyniak E., Gomez L.M., Inbody S.H., Mulcahy E.R., Culley N., Pinson D.M., Powers M.F., Wong S.W., and Stephens E.B. Scrambling of the amino acids within the transmembrane domain of Vpu results in a simian-human immunodeficiency virus (SHIV(TM)) that is less pathogenic for pig-tailed macaques. Virology 339 (2005) 56-69
73. Hout D.R., Gomez L.M., Pacyniak E., Miller J.M., Hill M.S., and Stephens E.B. A single amino acid substitution within the transmembrane domain of the human immunodeficiency virus type 1 Vpu protein renders simian-human immunodeficiency virus (SHIV(KU-1bMC33)) susceptible to rimantadine. Virology 348 (2006) 449-461
74. Hout D.R., Gomez M.L., Pacyniak E., Gomez L.M., Fegley B., Mulcahy E.R., Hill M.S., Culley N., Pinson D.M., Nothnick W., Powers M.F., Wong S.W., et al. Substitution of the transmembrane domain of Vpu in simian-human immunodeficiency virus (SHIV(KU1bMC33)) with that of M2 of influenza A results in a virus that is sensitive to inhibitors of the M2 ion channel and is pathogenic for pig-tailed macaques. Virology 344 (2006) 541-559
75. Hsu K., Seharaseyon J., Dong P., Bour S., and Marban E. Mutual functional destruction of HIV-1 Vpu and host TASK-1 channel. Mol. Cell 14 (2004) 259-267
76. Huet T., Cheynier R., Meyerhans A., Roelants G., and Wain-Hobson S. Genetic organization of a chimpanzee lentivirus related to HIV-1. Nature 345 (1990) 356-359
77. Huvent I., Hong S.S., Fournier C., Gay B., Tournier J., Carriere C., Courcoul M., Vigne R., Spire B., and Boulanger P. Interaction and co-encapsidation of human immunodeficiency virus type 1 Gag and Vif recombinant proteins. J. Gen. Virol. 79 Pt. 5 (1998) 1069-1081
78. Jabbar M.A., and Nayak D.P. Intracellular interaction of human immunodeficiency virus type 1 (ARV-2) envelope glycoprotein gp160 with CD4 blocks the movement and maturation of CD4 to the plasma membrane. J. Virol. 64 (1990) 6297-6304
79. Kao S., Akari H., Khan M.A., Dettenhofer M., Yu X.F., and Strebel K. Human immunodeficiency virus type 1 Vif is efficiently packaged into virions during productive but not chronic infection. J. Virol. 77 (2003) 1131-1140
80. Kao S., Miyagi E., Khan M.A., Takeuchi H., Opi S., Goila-Gaur R., and Strebel K. Production of infectious human immunodeficiency virus type 1 does not require depletion of APOBEC3G from virus-producing cells. Retrovirology 1 (2004) 27
81. Karczewski M.K., and Strebel K. Cytoskeleton association and virion incorporation of the human immunodeficiency virus type 1 Vif protein. J. Virol. 70 (1996) 494-507
82. Khan M.A., Aberham C., Kao S., Akari H., Gorelick R., Bour S., and Strebel K. Human immunodeficiency virus type 1 Vif protein is packaged into the nucleoprotein complex through an interaction with viral genomic RNA. J. Virol. 75 (2001) 7252-7265
83. Khan M.A., Kao S., Miyagi E., Takeuchi H., Goila-Gaur R., Opi S., Gipson C.L., Parslow T.G., Ly H., and Strebel K. Viral RNA is required for the association of APOBEC3G with human immunodeficiency virus type 1 nucleoprotein complexes. J. Virol. 79 (2005) 5870-5874
84. Kishi M., Nishino Y., Sumiya M., Ohki K., Kimura T., Goto T., Nakai M., Kakinuma M., and Ikuta K. Cells surviving infection by human immunodeficiency virus type 1: Vif or vpu mutants produce non-infectious or markedly less cytopathic viruses. J. Gen. Virol. 73 Pt. 1 (1992) 77-87
85. Klimkait T., Strebel K., Hoggan M.D., Martin M.A., and Orenstein J.M. The human immunodeficiency virus type 1-specific protein vpu is required for efficient virus maturation and release. J. Virol. 64 (1990) 621-629
86. Kochendoerfer G.G., Jones D.H., Lee S., Oblatt-Montal M., Opella S.J., and Montal M. Functional characterization and NMR spectroscopy on full-length Vpu from HIV-1 prepared by total chemical synthesis. J. Am. Chem. Soc. 126 (2004) 2439-2446
87. Kondo E., Mammano F., Cohen E.A., and Gottlinger H.G. The p6gag domain of human immunodeficiency virus type 1 is sufficient for the incorporation of Vpr into heterologous viral particles. J. Virol. 69 (1995) 2759-2764
88. Kotler M., Simm M., Zhao Y.S., Sova P., Chao W., Ohnona S.F., Roller R., Krachmarov C., Potash M.J., and Volsky D.J. Human immunodeficiency virus Type 1 (HIV-1) protein Vif inhibits the activity of HIV-1 protease in bacteria and in vitro. J. Virol. 71 (1997) 5774-5781
89. Kozak S.L., Marin M., Rose K.M., Bystrom C., and Kabat D. The anti-HIV-1 editing enzyme APOBEC3G binds HIV-1 RNA and messenger RNAs that shuttle between polysomes and stress granules. J. Biol. Chem. 281 39 (2006) 29105-29119
90. Kukol A., and Arkin I.T. vpu transmembrane peptide structure obtained by site-specific fourier transform infrared dichroism and global molecular dynamics searching. Biophys. J. 77 (1999) 1594-1601
91. Kusk P., Lindhardt B.O., Bugge T.H., Holmback K., and Hulgaard E.F. Mapping of a new immunodominant human linear B-cell epitope on the vpu protein of the human immunodeficiency virus type 1. J. Acquir. Immune Defic. Syndr. 6 (1993) 334-338
92. Lavallee C., Yao X.J., Ladha A., Gottlinger H., Haseltine W.A., and Cohen E.A. Requirement of the Pr55gag precursor for incorporation of the Vpr product into human immunodeficiency virus type 1 viral particles. J. Virol. 68 (1994) 1926-1934
93. Lemaitre V., Willbold D., Watts A., and Fischer W.B. Full length Vpu from HIV-1: Combining molecular dynamics simulations with NMR Spectroscopy. J. Biomol. Struct. Dyn. 23 (2006) 485-496
94. Li J.T., Halloran M., Lord C.I., Watson A., Ranchalis J., Fung M., Letvin N.L., and Sodroski J.G. Persistent infection of macaques with simian-human immunodeficiency viruses. J. Virol. 69 (1995) 7061-7067
95. Liddament M.T., Brown W.L., Schumacher A.J., and Harris R.S. APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo. Curr. Biol. 14 (2004) 1385-1391
96. Liu H., Wu X., Newman M., Shaw G.M., Hahn B.H., and Kappes J.C. The Vif protein of human and simian immunodeficiency viruses is packaged into virions and associates with viral core structures. J. Virol. 69 (1995) 7630-7638
97. Lu Y.L., Spearman P., and Ratner L. Human immunodeficiency virus type 1 viral protein R localization in infected cells and virions. J. Virol. 67 (1993) 6542-6550
98. Lu Y.L., Bennett R.P., Wills J.W., Gorelick R., and Ratner L. A leucine triplet repeat sequence (LXX)4 in p6gag is important for Vpr incorporation into human immunodeficiency virus type 1 particles. J. Virol. 69 (1995) 6873-6879
99. Luo K., Xiao Z., Ehrlich E., Yu Y., Liu B., Zheng S., and Yu X.F. Primate lentiviral virion infectivity factors are substrate receptors that assemble with cullin 5-E3 ligase through a HCCH motif to suppress APOBEC3G. Proc. Natl. Acad. Sci. USA 102 (2005) 11444-11449
100. Ma X.Y., Sova P., Chao W., and Volsky D.J. Cysteine residues in the Vif protein of human immunodeficiency virus type 1 are essential for viral infectivity. J. Virol. 68 (1994) 1714-1720
101. Mackay G.A., Niu Y., Liu Z.Q., Mukherjee S., Li Z., Adany I., Buch S., Zhuge W., McClure H.M., Narayan O., and Smith M.S. Presence of Intact vpu and nef genes in nonpathogenic SHIV is essential for acquisition of pathogenicity of this virus by serial passage in macaques. Virology 295 (2002) 133-146
102. Madani N., and Kabat D. An endogenous inhibitor of human immunodeficiency virus in human lymphocytes is overcome by the viral Vif protein. J. Virol. 72 (1998) 10251-10255
103. Maldarelli F., Chen M.Y., Willey R.L., and Strebel K. Human immunodeficiency virus type 1 Vpu protein is an oligomeric type I integral membrane protein. J. Virol. 67 (1993) 5056-5061
104. Mangeat B., Turelli P., Liao S., and Trono D. A single amino acid determinant governs the species-specific sensitivity of APOBEC3G to Vif action. J. Biol. Chem. 279 (2004) 14481-14483
105. Margottin F., Bour S.P., Durand H., Selig L., Benichou S., Richard V., Thomas D., Strebel K., and Benarous R. A novel human WD protein, h-beta TrCp, that interacts with HIV-1 Vpu connects CD4 to the ER degradation pathway through an F-box motif. Mol. Cell. 1 (1998) 565-574
106. Mariani R., Chen D., Schrofelbauer B., Navarro F., Konig R., Bollman B., Munk C., Nymark-McMahon H., and Landau N.R. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 114 (2003) 21-31
107. Marin M., Rose K.M., Kozak S.L., and Kabat D. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat. Med. 9 (2003) 1398-1403
108. McCormick-Davis C., Zhao L.J., Mukherjee S., Leung K., Sheffer D., Joag S.V., Narayan O., and Stephens E.B. Chronology of genetic changes in the vpu, env, and nef genes of chimeric simian-human immunodeficiency virus (strain HXB2) during acquisition of virulence for pig-tailed macaques. Virology 248 (1998) 275-283
109. McCormick-Davis C., Dalton S.B., Hout D.R., Singh D.K., Berman N.E., Yong C., Pinson D.M., Foresman L., and Stephens E.B. A molecular clone of simian-human immunodeficiency virus (DeltavpuSHIV(KU-1bMC33)) with a truncated, non-membrane-bound vpu results in rapid CD4(+) T cell loss and neuro-AIDS in pig-tailed macaques. Virology 272 (2000) 112-126
110. Mehle A., Goncalves J., Santa-Marta M., McPike M., and Gabuzda D. Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation. Genes Dev. 18 (2004) 2861-2866
111. Mehle A., Strack B., Ancuta P., Zhang C., McPike M., and Gabuzda D. Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. J. Biol. Chem. 279 (2004) 7792-7798
112. Mehle A., Thomas E.R., Rajendran K.S., and Gabuzda D. A zinc-binding region in Vif binds Cul5 and determines cullin selection. J. Biol. Chem. 281 (2006) 17259-17265
113. Meusser B., and Sommer T. Vpu-mediated degradation of CD4 reconstituted in yeast reveals mechanistic differences to cellular ER-associated protein degradation. Mol. Cell 14 (2004) 247-258
114. Neer E.J., Schmidt C.J., Nambudripad R., and Smith T.F. The ancient regulatory-protein family of WD-repeat proteins. Nature 371 (1994) 297-300
115. Neil S.J., Eastman S.W., Jouvenet N., and Bieniasz P.D. HIV-1 Vpu promotes release and prevents endocytosis of nascent retrovirus particles from the plasma membrane. PLoS Pathog. 2 (2006) e39
116. Oberste M.S., and Gonda M.A. Conservation of amino-acid sequence motifs in lentivirus Vif proteins. Virus Genes 6 (1992) 95-102
117. Ochsenbauer C., Wilk T., and Bosch V. Analysis of vif-defective human immunodeficiency virus type 1 (HIV-1) virions synthesized in 'non-permissive' T lymphoid cells stably infected with selectable HIV-1. J. Gen. Virol. 78 Pt. 3 (1997) 627-635
118. Ohno H., Aguilar R.C., Fournier M.C., Hennecke S., Cosson P., and Bonifacino J.S. Interaction of endocytic signals from the HIV-1 envelope glycoprotein complex with members of the adaptor medium chain family. Virology 238 (1997) 305-315
119. Opella S.J., Park S., Lee S., Jones D., Nevzorov A., Meslet M., Mrse A., Marassi F.M., Oblatt-Montal M., Montal M., Strebel K., and Bour S. Structure and function of Vpu from HIV-1. In: Fischer W. (Ed). "Viral Membrane Proteins: Structure, Function, and Drug Design" (2005), Kluwer Academic, New York 147-163
120. Pahl H.L. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 18 (1999) 6853-6866
121. Park S.H., and Opella S.J. Tilt angle of a trans-membrane helix is determined by hydrophobic mismatch. J. Mol. Biol. 350 (2005) 310-318
122. Park S.H., Mrse A.A., Nevzorov A.A., Mesleh M.F., Oblatt-Montal M., Montal M., and Opella S.J. Three-dimensional structure of the channel-forming trans-membrane domain of virus protein "U" (Vpu) from HIV-1. J. Mol. Biol. 333 (2003) 409-424
123. Paul I., Cui J., and Maynard E.L. Zinc binding to the HCCH motif of HIV-1 Virion infectivity factor induces a conformational change that mediates protein-protein interactions. Proc. Natl. Acad. Sci. USA 103 (2006) 18475-18480
124. Paul M., and Jabbar M.A. Phosphorylation of both phosphoacceptor sites in the HIV-1 Vpu cytoplasmic domain is essential for Vpu-mediated ER degradation of CD4. Virology 232 (1997) 207-216
125. Paul M., Mazumder S., Raja N., and Jabbar M.A. Mutational analysis of the human immunodeficiency virus type 1 Vpu transmembrane domain that promotes the enhanced release of virus-like particles from the plasma membrane of mammalian cells. J. Virol. 72 (1998) 1270-1279
126. Paxton W., Connor R.I., and Landau N.R. Incorporation of Vpr into human immunodeficiency virus type 1 virions: Requirement for the p6 region of gag and mutational analysis. J. Virol. 67 (1993) 7229-7237
127. Potash M.J., Bentsman G., Muir T., Krachmarov C., Sova P., and Volsky D.J. Peptide inhibitors of HIV-1 protease and viral infection of peripheral blood lymphocytes based on HIV-1 Vif. Proc. Natl. Acad. Sci. USA 95 (1998) 13865-13868
128. Ramiro A.R., Stavropoulos P., Jankovic M., and Nussenzweig M.C. Transcription enhances AID-mediated cytidine deamination by exposing single-stranded DNA on the nontemplate strand. Nat. Immunol. 4 (2003) 452-456
129. Reddy T.R., Kraus G., Yamada O., Looney D.J., Suhasini M., and Wong-Staal F. Comparative analyses of human immunodeficiency virus type 1 (HIV-1) and HIV-2 Vif mutants. J. Virol. 69 (1995) 3549-3553
130. Reiss Y., and Hershko A. Affinity purification of ubiquitin-protein ligase on immobilized protein substrates. J. Biol. Chem. 265 (1990) 3685-3690
131. Ritter G.D., Yamshchikov G., Cohen S.J., and Mulligan M.J. Human immunodeficiency virus type 2 glycoprotein enhancement of particle budding: Role of the cytoplasmic domain. J. Virol. 70 (1996) 2669-2673
132. Sakai H., Shibata R., Sakuragi J., Sakuragi S., Kawamura M., and Adachi A. Cell-dependent requirement of human immunodeficiency virus type 1 Vif protein for maturation of virus particles. J. Virol. 67 (1993) 1663-1666
133. Santa-Marta M., da Silva F.A., Fonseca A.M., and Goncalves J. HIV-1 Vif can directly inhibit apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G-mediated cytidine deamination by using a single amino acid interaction and without protein degradation. J. Biol. Chem. 280 (2005) 8765-8775
134. Santa-Marta M., Aires da Silva F., Fonseca A.M., Rato S., and Goncalves J. HIV-1 Vif protein blocks the cytidine deaminase activity of B-cell specific AID in E. coli by a similar mechanism of action. Mol. Immunol. 44 (2007) 583-590
135. Schatz O., Oft M., Dascher C., Schebesta M., Rosorius O., Jaksche H., Dobrovnik M., Bevec D., and Hauber J. Interaction of the HIV-1 rev cofactor eukaryotic initiation factor 5A with ribosomal protein L5. Proc. Natl. Acad. Sci. USA 95 (1998) 1607-1612
136. Schneider J., Lüke W., Kirchhoff F., Jung R., Jurkewicz E., Stahl-Henning C., Nick S., Klemm E., Jentsch K.D., and Hunsmann G. Isolation and characterization of HIV-2ben obtained from a patient with predominantly neurological defects. Aids 4 (1990) 455-457
137. Schneider T., Hildebrandt P., Rönspeck W., Weigelt W., and Pauli G. The antibody response to the HIV-1 specific "out" (vpu) protein: Identification of an immunodominant epitope and correlation of antibody detectability to clinical stages. AIDS Res. Hum. Retrovir. 6 (1990) 943-950
138. Schrofelbauer B., Chen D., and Landau N.R. A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif). Proc. Natl. Acad. Sci. USA 101 (2004) 3927-3932
139. Schrofelbauer B., Senger T., Manning G., and Landau N.R. Mutational alteration of human immunodeficiency virus type 1 Vif allows for functional interaction with nonhuman primate APOBEC3G. J. Virol. 80 (2006) 5984-5991
140. Schubert U., and Strebel K. Differential activities of the human immunodeficiency virus type 1-encoded Vpu protein are regulated by phosphorylation and occur in different cellular compartments. J. Virol. 68 (1994) 2260-2271
141. Schubert U., Henklein P., Boldyreff B., Wingender E., Strebel K., and Porstmann T. The human immunodeficiency virus type 1 encoded Vpu protein is phosphorylated by casein kinase-2 (CK-2) at positions Ser52 and Ser56 within a predicted alpha-helix-turn-alpha-helix-motif. J. Mol. Biol. 236 (1994) 16-25
142. Schubert U., Bour S., Ferrer-Montiel A.V., Montal M., Maldarell F., and Strebel K. The two biological activities of human immunodeficiency virus type 1 Vpu protein involve two separable structural domains. J. Virol. 70 (1996) 809-819
143. Schubert U., Ferrer-Montiel A.V., Oblatt-Montal M., Henklein P., Strebel K., and Montal M. Identification of an ion channel activity of the Vpu transmembrane domain and its involvement in the regulation of virus release from HIV-1-infected cells. FEBS Lett. 398 (1996) 12-18
144. Schubert U., Anton L.C., Bacik I., Cox J.H., Bour S., Bennink J.R., Orlowski M., Strebel K., and Yewdell J.W. CD4 glycoprotein degradation induced by human immunodeficiency virus type 1 Vpu protein requires the function of proteasomes and the ubiquitin-conjugating pathway. J. Virol. 72 (1998) 2280-2288
145. Schubert U., Bour S., Willey R.L., and Strebel K. Regulation of virus release by the macrophage-tropic human immunodeficiency virus type 1 AD8 isolate is redundant and can be controlled by either Vpu or Env. J. Virol. 73 (1999) 887-896
146. Schwartz S., Felber B.K., Fenyö E.M., and Pavlakis G.N. Env and vpu proteins of human immunodeficiency virus type-1 are produced from multiple bicistronic mRNAs. J. Virol. 64 (1990) 5448-5456
147. Schwartz S., Felber B.K., and Pavlakis G.N. Expression of human immunodeficiency virus type 1 vif and vpr mRNAs is Rev-dependent and regulated by splicing. Virology 183 (1991) 677-686
148. Selig L., Pages J.C., Tanchou V., Preveral S., Berlioz-Torrent C., Liu L.X., Erdtmann L., Darlix J., Benarous R., and Benichou S. Interaction with the p6 domain of the gag precursor mediates incorporation into virions of Vpr and Vpx proteins from primate lentiviruses. J. Virol. 73 (1999) 592-600
149. Sharpe S., Yau W.M., and Tycko R. Structure and dynamics of the HIV-1 Vpu transmembrane domain revealed by solid-state NMR with magic-angle spinning. Biochemistry 45 (2006) 918-933
150. Sheehy A.M., Gaddis N.C., Choi J.D., and Malim M.H. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418 (2002) 646-650
151. Sheehy A.M., Gaddis N.C., and Malim M.H. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat. Med. 9 (2003) 1404-1407
152. Simm M., Shahabuddin M., Chao W., Allan J.S., and Volsky D.J. Aberrant Gag protein composition of a human immunodeficiency virus type 1 vif mutant produced in primary lymphocytes. J. Virol. 69 (1995) 4582-4586
153. Simon J.H., Southerling T.E., Peterson J.C., Meyer B.E., and Malim M.H. Complementation of vif-defective human immunodeficiency virus type 1 by primate, but not nonprimate, lentivirus vif genes. J. Virol. 69 (1995) 4166-4172
154. Simon J.H., Fouchier R.A., Southerling T.E., Guerra C.B., Grant C.K., and Malim M.H. The Vif and Gag proteins of human immunodeficiency virus type 1 colocalize in infected human T cells. J. Virol. 71 (1997) 5259-5267
155. Simon J.H., Gaddis N.C., Fouchier R.A., and Malim M.H. Evidence for a newly discovered cellular anti-HIV-1 phenotype. Nat. Med. 4 (1998) 1397-1400
156. Simon J.H., Miller D.L., Fouchier R.A., and Malim M.H. Virion incorporation of human immunodeficiency virus type-1 Vif is determined by intracellular expression level and may not be necessary for function. Virology 248 (1998) 182-187
157. Simon J.H., Miller D.L., Fouchier R.A., Soares M.A., Peden K.W., and Malim M.H. The regulation of primate immunodeficiency virus infectivity by Vif is cell species restricted: A role for Vif in determining virus host range and cross-species transmission. EMBO J. 17 (1998) 1259-1267
158. Simon J.H., Sheehy A.M., Carpenter E.A., Fouchier R.A., and Malim M.H. Mutational analysis of the human immunodeficiency virus type 1 Vif protein. J. Virol. 73 (1999) 2675-2681
159. Singh D.K., Griffin D.M., Pacyniak E., Jackson M., Werle M.J., Wisdom B., Sun F., Hout D.R., Pinson D.M., Gunderson R.S., Powers M.F., Wong S.W., et al. The presence of the casein kinase II phosphorylation sites of Vpu enhances the CD4(+) T cell loss caused by the simian-human immunodeficiency virus SHIV(KU-lbMC33) in pig-tailed macaques. Virology 313 (2003) 435-451
160. Skowyra D., Koepp D.M., Kamura T., Conrad M.N., Conaway R.C., Conaway J.W., Elledge S.J., and Harper J.W. Reconstitution of G1 cyclin ubiquitination with complexes containing SCFGrr1 and Rbx1. Science 284 (1999) 662-665
161. Sova P., and Volsky D.J. Efficiency of viral DNA synthesis during infection of permissive and nonpermissive cells with vif-negative human immunodeficiency virus type 1. J. Virol. 67 (1993) 6322-6326
162. Sova P., Chao W., and Volsky D.J. The redox state of cysteines in human immunodeficiency virus type 1 Vif in infected cells and in virions. Biochem. Biophys. Res. Commun. 240 (1997) 257-260
163. Spencer E., Jiang J., and Chen Z.J. Signal-induced ubiquitination of IkappaBalpha by the F-box protein Slimb/beta-TrCP. Genes Dev. 13 (1999) 284-294
164. Spevak W., Keiper B.D., Stratowa C., and Castanon M.J. Saccharomyces cerevisiae cdc15 mutants arrested at a late stage in anaphase are rescued by xenopus cDNAs encoding N-ras or a protein with beta-transducin repeats. Mol. Cell. Biol. 13 (1993) 4953-4966
165. Stephens E.B., Mukherjee S., Sahni M., Zhuge W., Raghavan R., Singh D.K., Leung K., Atkinson B., Li Z., Joag S.V., Liu Z.Q., and Narayan O. A cell-free stock of simian-human immunodeficiency virus that causes AIDS in pig-tailed macaques has a limited number of amino acid substitutions in both SIVmac and HIV-1 regions of the genome and has offered cytotropism. Virology 231 (1997) 313-321
166. Stephens E.B., McCormick C., Pacyniak E., Griffin D., Pinson D.M., Sun F., Nothnick W., Wong S.W., Gunderson R., Berman N.E., and Singh D.K. Deletion of the vpu sequences prior to the env in a Simian-Human immunodeficiency virus results in enhanced env precursor synthesis but is less pathogenic for pig-tailed macaques. Virology 293 (2002) 252-261
167. Stopak K., de Noronha C., Yonemoto W., and Greene W.C. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol. Cell 12 (2003) 591-601
168. Strebel K., Daugherty D., Clouse K., Cohen D., Folks T., and Martin M.A. The HIV 'A' (sor) gene product is essential for virus infectivity. Nature 328 (1987) 728-730
169. Strebel K., Klimkait T., and Martin M.A. A novel gene of HIV-1, vpu, and its 16-kilodalton product. Science 241 (1988) 1221-1223
170. Strebel K., Klimkait T., Maldarelli F., and Martin M.A. Molecular and biochemical analyses of human immunodeficiency virus type 1 vpu protein. J. Virol. 63 (1989) 3784-3791
171. Terwilliger E.F., Cohen E.A., Lu Y., Sodroski J.G., and Haseltine W.A. Functional role of human immunodeficiency virus type 1 vpu. Proc. Natl. Acad. Sci. USA 86 (1989) 5163-5167
172. Varthakavi V., Smith R.M., Bour S.P., Strebel K., and Spearman P. Viral protein U counteracts a human host cell restriction that inhibits HIV-1 particle production. Proc. Natl. Acad. Sci. USA 100 (2003) 15154-15159
173. Varthakavi V., Smith R.M., Martin K.L., Derdowski A., Lapierre L.A., Goldenring J.R., and Spearman P. The pericentriolar recycling endosome plays a key role in Vpu-mediated enhancement of HIV-1 particle release. Traffic 7 (2006) 298-307
174. von Schwedler U., Song J., Aiken C., and Trono D. Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells. J. Virol. 67 (1993) 4945-4955
175. Wiegand H.L., Doehle B.P., Bogerd H.P., and Cullen B.R. A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. EMBO J. 23 (2004) 2451-2458
176. Wiertz E.J., Jones T.R., Sun L., Bogyo M., Geuze H.J., and Ploegh H.L. The human cytomegalovirus US11 gene product dislocates MHC class I heavy chains from the endoplasmic reticulum to the cytosol. Cell 84 (1996) 769-779
177. Willbold D., Hoffmann S., and Roesch P. Secondary structure and tertiary fold of the human immunodeficiency virus protein U (Vpu) cytoplasmic domain in solution. Eur. J. Biochem. 245 (1997) 581-588
178. Willey R.L., Maldarelli F., Martin M.A., and Strebel K. Human immunodeficiency virus type 1 Vpu protein regulates the formation of intracellular gp160-CD4 complexes. J. Virol. 66 (1992) 226-234
179. Willey R.L., Maldarelli F., Martin M.A., and Strebel K. Human immunodeficiency virus type 1 Vpu protein induces rapid degradation of CD4. J. Virol. 66 (1992) 7193-7200
180. Winston J.T., Strack P., Beer-Romero P., Chu C.Y., Elledge S.J., and Harper J.W. The SCFbeta-TRCP-ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in IkappaBalpha and beta-catenin and stimulates IkappaBalpha ubiquitination in vitro. Genes Dev. 13 (1999) 270-283
181. Wray V., Federau T., Henklein P., Klabunde S., Kunert O., Schomburg D., and Schubert U. Solution structure of the hydrophilic region of HIV-1 encoded virus protein U (Vpu) by CD and 1H NMR spectroscopy. Int. J. Peptide Protein Res. 45 (1995) 35-43
182. Xiao Z., Ehrlich E., Yu Y., Luo K., Wang T., Tian C., and Yu X.F. Assembly of HIV-1 Vif-Cul5 E3 ubiquitin ligase through a novel zinc-binding domain-stabilized hydrophobic interface in Vif. Virology 349 (2006) 290-299
183. Xu H., Svarovskaia E.S., Barr R., Zhang Y., Khan M.A., Strebel K., and Pathak V.K. A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion. Proc. Natl. Acad. Sci. USA 101 (2004) 5652-5657
184. Yang S., Sun Y., and Zhang H. The multimerization of human immunodeficiency virus type I Vif protein: A requirement for Vif function in the viral life cycle. J. Biol. Chem. 276 (2001) 4889-4893
185. Yang X., and Gabuzda D. Mitogen-activated protein kinase phosphorylates and regulates the HIV-1 Vif protein. J. Biol. Chem. 273 (1998) 29879-29887
186. Yang X., Goncalves J., and Gabuzda D. Phosphorylation of Vif and its role in HIV-1 replication. J. Biol. Chem. 271 (1996) 10121-10129
187. Yao X.J.Y., Goettlinger H., Haseltine W.A., and Cohen E.A. Envelope glycoprotein and CD4 independence of Vpu-facilitated human immunodeficiency virus type 1 capsid export. J. Virol. 66 (1992) 5119-5126
188. Yaron A., Hatzubai A., Davis M., Lavon I., Amit S., Manning A.M., Andersen J.S., Mann M., Mercurio F., and Ben-Neriah Y. Identification of the receptor component of the IkappaBalpha-ubiquitin ligase. Nature 396 (1998) 590-594
189. Yu X., Yu Y., Liu B., Luo K., Kong W., Mao P., and Yu X.F. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302 (2003) 1056-1060
190. Yu Y., Xiao Z., Ehrlich E.S., Yu X., and Yu X.F. Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines. Genes Dev. 18 (2004) 2867-2872
191. Yusim K., Kesmir C., Gaschen B., Addo M.M., Altfeld M., Brunak S., Chigaev A., Detours V., and Korber B.T. Clustering patterns of cytotoxic T-lymphocyte epitopes in human immunodeficiency virus type 1 (HIV-1) proteins reveal imprints of immune evasion on HIV-1 global variation. J. Virol. 76 (2002) 8757-8768
192. Zhang H., Pomerantz R.J., Dornadula G., and Sun Y. Human immunodeficiency virus type 1 vif protein is an integral component of an mRNP complex of viral RNA and could be involved in the viral RNA folding and packaging process. J. Virol. 74 (2000) 8252-8261
193. Zheng S., Strzalka J., Jones D.H., Opella S.J., and Blasie J.K. Comparative structural studies of Vpu peptides in phospholipid monolayers by X-ray scattering. Biophys. J. 84 (2003) 2393-2415